Making the Transition to CE Methods and between CE Methods- An FDA Reviewer s Perspective
|
|
- Lucas Lester
- 6 years ago
- Views:
Transcription
1 Making the Transition to CE Methods and between CE Methods- An FDA Reviewer s Perspective Sarah Kennett, Ph.D. Division of Monoclonal Antibodies Office of Biotechnology Products OPS/CDER/FDA October 15, 2008
2 Disclaimer The opinions presented by the speaker may not reflect FDA policy.
3 Overview Not a talk about how to validate a new method Methods we currently see being used Changes that are being made Things to think about when making changes in your analytical methods and submitting changes to the FDA
4 OBP/OPS/CDER Office of the Director Steven Kozlowski, M.D., Director Division of Monoclonal Antibodies Kathleen Clouse, Ph.D., Director Division of Therapeutic Proteins Amy Rosenberg, Ph.D., Director Monoclonal Antibodies Enzymes Fc - Fusion Proteins Cytokines Growth factors Toxins Adapted from M. Frazier-Jessen CE Pharm 2006
5 Attributes & Combinatorics pyro-e D O O G D D G K K D 2 x 6 x 4 x 4 x 5 x 5 x 2 = 9600 D G G O O D pyro-e Pyro-Glu (2) Deamidation (3 x 2) Methionine oxidation (2 x 2) Glycation (2 x 2) High mannose, G0, G1, G1, G2 (5) Sialylation (5) C-term Lys (2) (9600) Adapted from M. Frazier-Jessen CE Pharm 2006
6 Therefore. Suitable analytical methods (CE!) are needed to characterize/assess/monitor the complexities associated with biotechnology products (and other therapeutics) in order to assure: Quality Safety Efficacy Adapted from M. Frazier-Jessen CE Pharm 2006
7 CE applications Small molecules Carbohydrates Nucleic acids Proteins Size heterogeneity Charge heterogeneity Identity Oligosaccharide profile
8 Capillary Electrophoresis and Biotechnology Products cief/imaged cief, CZE, reducing/non-reducing CGE (CE-SDS) Characterization/Development In Process Testing Lot Release Stability Comparability
9 Current types of changes Heparin USP updated monograph June 18, 2008 includes a revised version of the FDA CE method SDS-PAGE to CE-SDS reduced and non-reduced IEF to cief CEX-HPLC to cief CE version 1 to CE version 2
10 Things to be considered- Part 1 Method Qualification/Validation The ability to demonstrate Accuracy, Precision (Repeatability, Reproducibility, Intermediate Precision), Specificity, Detection Limit, Quantitation Limit, Linearity, Range, Robustness are major considerations when selecting and developing an analytical method.
11 Things to be considered-part 2 De-identified examples Data pairs (same material) Not necessarily meant to support a change in method
12 Non-reduced SDS-PAGE vs. Non-reduced CE-SDS reference Process 1 Process 2 Proc 2 Proc 1 Ref.
13 Non-reduced SDS-PAGE vs. Non-reduced CE-SDS Bands in gel but not CE Bands are product-related Some possibilities Gel bands could be due to sample prep artifacts Bands could be due to increased loading on gels Tell us! Know your product-know what the bands/peaks represent Know what different sample preps look like Know the loading differences Know what your assay tells you Do you need to be able to monitor the species that do not appear when using the CE method? CE-SDS is more quantitative and more stability indicating. Given all information, this change was considered to be acceptable.
14 Reduced SDS-PAGE vs. Reduced CE-SDS HC LC Tell us! Non-glycosylated heavy chain
15 CEX-HPLC vs. cief Tell us!
16 IEF vs. cief
17 IEF vs. cief cief appears to not be as stability-indicating as IEF IEF is the most stability-indicating assay Know what your assay tells you. Be mindful of your specifications when you change your assay. Some differences may be accounted for by adjustments in acceptance criteria. Change is not yet acceptable. Need to provide evidence that cief is as stability-indicating
18 IEF vs. cief cief appears to not be as stability-indicating as IEF IEF is the most stability-indicating assay Know what your assay tells you. Be mindful of your specifications when you change your assay. Some differences may be accounted for by adjustments in acceptance criteria. When the method is part of your stability protocol, you may need to run the old and new method side-by-side for a number of lots to show that you detect the same degradation pattern and detect the changes in the product at the same rate.
19 cief protocol 1 vs. cief protocol 2 Old manufacturing process New process Lot number Reference Standard Lot A Lot B Lot XYZ cief 6 peaks 6 peaks 6 peaks 9 peaks More peaks using a new cief protocol Run old and new materials side-by-side using the new method You may need studies to show that you can compare your old and new data.
20 Identity Protein A vs. Protein B
21 Identity - Small differences Protein A vs. Protein B +/- C-terminal lysine
22 Identity - Small differences Protein A vs. Protein B Codeine vs. Morphine Heparin vs. OSCS
23 Identity - Small differences Big effect Protein A vs. Protein B Codeine vs. Morphine Heparin vs. OSCS Statistics Type I vs. Type II error
24 Things to consider-part 3 System (Know what your assay tells you) Detectors (LIF, MS) Corrected peak areas Controls Availability of materials, support, etc. System suitability tests (inspection) Personnel Training/SOPs (inspection)
25 Tangent Note to sponsors who would like to initiate their programs of development using CE methods. Please remember that the traditional methods do have a place in the development process, and you might want to run traditional analyses side-by-side with CE analyses until you (and FDA) are satisfied that the CE method is showing you everything you need to know.
26 Conclusions Consider aspects of validation/qualification Know what your current assay tells you and what information the new assay needs to provide You may need to run side-by-side analyses of old and new materials using the new assay You may need to run side-by-side analyses of old and new assays using the same material Provide to FDA any information that might be important for our review of your submissions
27 Acknowledgements Division of Monoclonal Antibodies Division of Therapeutic Proteins Patrick Swann Chana Fuchs Barbara Rellahan Laurie Graham Jack Ragheb Ruth Cordoba-Rodriguez Michele Dougherty Carla Lankford Jun Park Rashmi Rawat Ram Sihag Lixin Xu
Mass Spectrometry for Characterization of Monoclonal Antibodies: Regulatory Considerations
Mass Spectrometry for Characterization of Monoclonal Antibodies: Regulatory Considerations Jun Park, Ph.D. Division of Monoclonal Antibodies Office of Biotechnology Products OPS/CDER Food and Drug Administration
More informationCritical Quality Attributes for Biotechnology Products: A Regulatory Perspective
Critical Quality Attributes for Biotechnology Products: A Regulatory Perspective Patrick G. Swann, Ph.D. Deputy Director Division of Monoclonal Antibodies Office of Biotechnology Products Office of Pharmaceutical
More informationChanges to a Potency Bioassay for Biotechnology Products: a Regulatory Perspective Kathleen A. Clouse, Ph.D., Director Division of Monoclonal Antibodi
Changes to a Potency Bioassay for Biotechnology Products: a Regulatory Perspective Kathleen A. Clouse, Ph.D., Director Division of Monoclonal Antibodies Office of Biotechnology Products Center for Drug
More informationFDA recommendations for comparability studies to support manufacturing changes. Joslyn Brunelle, PhD Office of Biotechnology Products OPQ/CDER/FDA
FDA recommendations for comparability studies to support manufacturing changes Joslyn Brunelle, PhD Office of Biotechnology Products OPQ/CDER/FDA The views and opinions expressed here should not be used
More informationAntibody-Drug Conjugate Characterization and Quality Assurance
Antibody-Drug Conjugate Characterization and Quality Assurance Sarah Kennett Division of Monoclonal Antibodies Office of Biotechnology Products OPS/CDER/FDA October 12, 2011 1 Disclaimer The views and
More informationPrioritizing and Managing Key CMC Elements
Prioritizing and Managing Key CMC Elements Using 21 st Century Principles during Early Development Laurie Graham Product Quality/CMC Reviewer FDA/CDER/OPS/OBP Division of Monoclonal Antibodies 1 Disclaimer
More informationThe United States Pharmacopeia Strategy on Biotherapeutic Products Standards. Jaap Venema, Ph.D. Chief Science Officer & Chair, Council of Experts
The United States Pharmacopeia Strategy on Biotherapeutic Products Standards Jaap Venema, Ph.D. Chief Science Officer & Chair, Council of Experts U.S. Pharmacopeia Who We Are Scientific, independent, volunteer-driven,
More informationRegulatory Perspective on Analytical Method Validation During Product Development
Regulatory Perspective on Analytical Method Validation During Product Development CASSS CMC Strategy Forum 2018 Jacek Cieslak CDER/OPQ/OBP FDA Disclaimer This presentation reflects the views of the author
More informationAnalysis of Protein Biopharmaceuticals
Analysis of Protein Biopharmaceuticals Comprehensive cgmp Services at Every Stage of Drug Development Amazing where you can go At Solvias, we work closely with you Solvias provides comprehensive services
More informationEstablishing Clonal Cell Lines A Regulatory Perspective
Establishing Clonal Cell Lines A Regulatory Perspective Black Cell, Blue Cell, Old Cell, New Cell? Sarah Kennett, Ph.D., Review Chief Division of Monoclonal Antibodies OBP/OPS/CDER/FDA WCBP 2014 January
More informationEffectively utilizing Post Translational Modification analysis to fast track process development for Biosimilars
Effectively utilizing Post Translational Modification analysis to fast track process development for Biosimilars Sanjeev Gupta DGM-Advanced Biotech (R&D) Ipca Laboratories Ltd., Mumbai, India March 04,
More informationCommon Issues in Qualification and Validation of Analytical Procedures
Common Issues in Qualification and Validation of Analytical Procedures Alexey Khrenov, PhD OTAT/CBER/FDA CMC Strategy Forum January 29, 2018 - Washington, DC Disclaimer These comments are an informal communication
More informationCapillary Electrophoresis in Pharmacopoeial Monographs
www.pei.de Capillary Electrophoresis in Pharmacopoeial Monographs Current Situation, Requirements and Obstacles Stefan Christians, Immunochemistry CE-Pharm 2011; Amelia Island The Big Bang in Astronomy
More informationRegulatory Considerations on. Office of Biotechnology Products
Regulatory Considerations on Multiproduct t Facilities for Biotechnology Products Jun Park, Ph.D. Division of Monoclonal Antibodies Office of Biotechnology Products OPS/CDER/FDA 2011 CASSS CMC Strategy
More informationAdvanced Applications of CE to Biotech Product Development: Monitoring quality from clone selection to final release
Advanced Applications of CE to Biotech Product Development: Monitoring quality from clone selection to final release Dr Flavie ROBERT Biotech Process Sciences, Merck Serono SA, CH CEPharm, Vancouver, 2010
More informationCharacterization of Biotechnology Products: A Regulatory Perspective
Characterization of Biotechnology Products: A Regulatory Perspective Laurie Graham Acting Team Leader FDA/CDER/OPS/OBP Division of Monoclonal Antibodies WCBP 2013 1 Disclaimer The views and opinions expressed
More informationScientific and Regulatory Perspectives on Measuring Protein Aggregation of Biotechnology Products
Scientific and Regulatory Perspectives on Measuring Protein Aggregation of Biotechnology Products Ashutosh Rao, Ph.D. Chief, Laboratory of Applied Biochemistry Division of Biotechnology Review and Research
More informationChallenges in peptide mapping mass spectrometry of biopharmaceuticals
Challenges in peptide mapping mass spectrometry of biopharmaceuticals Will Burkitt, Ben Holmes, Johanna Paris, Nisha Patel, John O Hara 07.MAR.2018 Characterisation within UCB 2 Context to the type of
More informationCapillary Electrophoresis Compendial Applications
Capillary Electrophoresis Compendial Applications Anita Szajek, Ph.D. Principal Scientific Liaison, Biologics & Biotechnology 14 th Symposium on the Practical Applications for the Analysis of Proteins,
More informationAn Industry Perspective on Established Conditions in the Analytical Control System. Christof Finkler, F. Hoffmann-La Roche
An Industry Perspective on Established Conditions in the Analytical Control System Christof Finkler, F. Hoffmann-La Roche Control System Development INPUT: Process Parameter OUTPUT: Quality Attribute CPPs
More informationMonitoring Charge Heterogeneity of Antibody-Maytansinoid Conjugates (AMC) with icief
Monitoring Charge Heterogeneity of Antibody-Maytansinoid Conjugates (AMC) with icief Joyce Lin, Rajesh Krishnamurthy, Alexandru Lazar ImmunoGen, Inc., Waltham, MA CE Pharm 2008 utline I. Introduction of
More informationStreamlined and Complete LC-MS Workflow for MAM
Streamlined and Complete LC-MS Workflow for MAM Multiple Attribute Methodology (MAM) for Biotherapeutic Attribute Monitoring and Purity Testing BV MAM WORKFLOW Define Track Quantify Purity New Peaks Report
More informationAssistant Professor Mohammad A Alsenaidy, MSc, PhD, Saudi Arabia
GaBI Scientific Meetings First GCC Stakeholder Meeting on Approval Process, Interchangeability/Substitution and Safety of Biosimilars 20 November 2017, Holiday Inn Izdihar Riyadh, Saudi Arabia Assistant
More informationLabChip GXII: Antibody Analysis
WHITE PAPER LabChip GXII: Antibody Analysis Antibody Analysis using microfluidic technology in high throughput Quality by Design Experiments Abstract Current initiatives in Process Analytical Technology
More informationDeveloping Robust and Efficient IEX Methods for Charge Variant Analysis of Biotherapeutics Using ACQUITY UPLC H-Class System and Auto Blend Plus
Developing Robust and Efficient IEX Methods for Charge Variant Analysis of Biotherapeutics Using ACQUITY UPLC H-Class System and Auto Blend Plus Robert Birdsall, Thomas Wheat, and Weibin Chen Waters Corporation,
More informationCE as an analytical tool in industrial biotechnology. David Goodall, CSO, Paraytec Ltd. 14 November Act P x
1 CE as an analytical tool in industrial biotechnology David Goodall, CSO, Paraytec Ltd 14 November 2013 Coverage 2 Modes of CE Industrial sectors for applications Companies and key markets Selected applications
More informationAn FDA Perspective on the Implementation of State-of-the-Art Analytical Methods for the Development of Therapeutic Proteins
An FDA Perspective on the Implementation of State-of-the-Art Analytical Methods for the Development of Therapeutic Proteins Marjorie Shapiro, Ph.D. Office of Biotechnology Products/FDA WCBP 2018 Technical
More informationThe Role of Mass Spectrometry for Developing Biotherapeutics: Regulatory Perspectives
The Role of Mass Spectrometry for Developing Biotherapeutics: Regulatory Perspectives Jun Park, Ph.D. Division of Monoclonal Antibodies Office of Biotechnology Products CDER/FDA CASSS, Applications of
More informationSDS-CGE Method Development for Purified Protein Vaccine Antigens
SDS-CGE Method Development for Purified Protein Vaccine Antigens Michael Leach, Elena Newman and Bruce Carpick Sanofi Pasteur Analytical R&D, Biochemistry Overview SDS-CGE method development for purified
More informationSeparation of Native Monoclonal Antibodies and Identification of Charge Variants:
Separation of Native Monoclonal Antibodies and Identification of Charge Variants: Teamwork of the Agilent 31 OFFGEL Fractionator, Agilent 21 Bioanalyzer and Agilent LC/MS Systems Application Note Biosimilar
More informationAssessment of Active Biopharmaceutical Ingredients Prior To and Following Removal of Interfering Excipients
Assessment of Active Biopharmaceutical Ingredients Prior To and Following Removal of Interfering Excipients Andrew J Reason and Howard R Morris BioPharmaSpec Ltd, and BioPharmaSpec Inc, The EMA guideline
More informationComprehensive characterization of three IgG forms using CESI-MS
Comprehensive characterization of three IgG forms using CESI-MS Bryan Fonslow 1, Olga V. Friese 2, and K. Steven Cook 2 1 SCIEX, Brea, CA and 2 Pfizer, Chesterfield, MO mabs, ADCs, biosimilars, and biobetters
More informationUnified Workflow for Monoclonal Antibody Charge Heterogeneity, Purity, and Molecular Weight Analysis
Procedures Unified Workflow for Monoclonal Antibody Charge Heterogeneity, Purity, and Molecular Weight Analysis Separation and Online Detection of Intact mab Variants and Impurities using CESI-MS Bryan
More informationA FDA Product Reviewer s Perspective on Building A Quality Dossier
A FDA Product Reviewer s Perspective on Building A Quality Dossier CASSS Mid-West Discussion Group October 29, 2015 University Center of Lake County, Grayslake, IL Howard Anderson, PhD Team Lead Product
More informationAutomated and quantitative analysis of biologics
PA 800 PLUS PHARMACEUTICAL ANALYSIS SYSTEM Automated and quantitative analysis of biologics PA 800 PLUS PHARMACEUTIC AL ANALYSIS SYSTEM Designed for the needs of the biopharmaceutical industry Therapeutic
More informationThis is not unique to CE. It took for instance about 25 years for HPLC to establish itself properly in the pharmaceutical industry.
CE Pharm 2017 Troubleshooting Report: CZE and CE-SDS the Discussion Continues Workshop facilitators: Tim Blanc 1, Cari Sänger-van de Griend 2 Scribes: Nathan Lacher 3, David Michels 4, Zoran Sosic 5 1
More informationAPPLICATION INFORMATION
A-1861A APPLICATION INFORMATION Capillary Electrophoresis USING CIEF TO CHARACTERIZE RECOMBINANT HUMAN MONOCLONAL ANTIBODIES L. C. Santosa, 1 I. S. Krull, 1 and K. L. Grant 2 1 Department of Chemistry,
More informationFDA Perspective: Recent Trends in the Regulation of Biopharmaceuticals
FDA Perspective: Recent Trends in the Regulation of Biopharmaceuticals CMC Strategy Forum LATAM 2014 Sarah Kennett, Ph.D. Division of Monoclonal Antibodies Office of Biotechnology Products OPS,CDER, FDA
More informationE VA L U AT I O N O F N E W T E C H N O L O GY F O R T H E Q U A L I T Y C O N T R O L L A B O R ATO R I E S JEFF SCHNEIDERHEINZE, PH.D.
E VA L U AT I O N O F N E W T E C H N O L O GY F O R T H E Q U A L I T Y C O N T R O L L A B O R ATO R I E S JEFF SCHNEIDERHEINZE, PH.D. 1 OUTLINE Background on Microchip CE (MCE) Extended Qualification
More informationExamples of regulatory expectations for analytical characterization and testing
Examples of regulatory expectations for analytical characterization and testing AT Europe 2016, 18 March 2016 Vicki Venizelos Quality RA B.V. Leiden, the Netherlands Overview What are the regulatory expectations?
More informationComparability Analysis of Protein Therapeutics by Bottom-Up LC-MS with Stable Isotope-Tagged Reference Standards
Comparability Analysis of Protein Therapeutics by Bottom-Up LC-MS with Stable Isotope-Tagged Reference Standards 16 September 2011 Abbott Bioresearch Center, Worcester, MA USA Manuilov, A. V., C. H. Radziejewski
More informationStability of Biological Products
Stability of Biological Products Dr Jurgen Lindner Principal, BioPharma Consulting & Executive Secretary, APIMAA Biological Products Functional Proteins or Polypeptides (mab s, enzymes & inhibitors, growth
More informationMolecular characterization, detection & quantitation of biological products Purin Charoensuksai, PhD
Molecular characterization, detection & quantitation of biological products Purin Charoensuksai, PhD Department of Biopharmacy, Faculty of Pharmacy, Silpakorn University Example of critical checkpoints
More informationThe Ludger GX-mAb Glycoprofiling Service High Throughput glycan analysis service of monoclonal antibodies (mabs) for drug developers and manufacturers
The Ludger GX-mAb Glycoprofiling Service High Throughput glycan analysis service of monoclonal antibodies (mabs) for drug developers and manufacturers Dr Richard Gardner Senior Chemist richard.gardner@ludger.com
More informationCapillary Electrophoresis Sodium Hexadecyl Sulfate (CE-SHS): A Novel Approach to Evaluate the Purity of Therapeutic Proteins
Capillary Electrophoresis Sodium Hexadecyl Sulfate (CE-SHS): A Novel Approach to Evaluate the Purity of Therapeutic Proteins Jeff Beckman Bristol Myers Squibb 1 OUTLINE 1.CE-SDS: Improvement Opportunities
More informationRisk Assessments for Host Cell Protein Control Strategies: CDER Experiences
Risk Assessments for Host Cell Protein Control Strategies: CDER Experiences Laurie Graham FDA/CDER Office of Pharmaceutical Quality (OPQ) Office of Policy for Pharmaceutical Quality (OPPQ) 1 Disclaimer
More informationRegulatory Perspectives on Higher Order Structure Evaluations for Protein Products. Emily Shacter, Ph.D.
Regulatory Perspectives on Higher Order Structure Evaluations for Protein Products Emily Shacter, Ph.D. Chief, Laboratory of Biochemistry U.S. Food and Drug Administration Center for Drug Evaluation and
More informationOptimization Approaches in the Routine Analysis of Monoclonal Antibodies by Capillary Electrophoresis
Optimization Approaches in the Routine Analysis of Monoclonal Antibodies by Capillary Electrophoresis Oscar Salas-Solano, Lynn Gennaro and Chantal Felten, Protein Analytical Chemistry Department, Process
More informationCASSS CMC Strategy Forum Barcelona, Spain. EBE Satellite Session Comparability Concept Paper 21 st March 2011
CASSS CMC Strategy Forum Barcelona, Spain EBE Satellite Session Comparability Concept Paper 21 st March 2011 Aim of concept paper Points to consider in planning and undertaking of comparability exercise
More informationIgG Purity/Heterogeneity and SDS-MW Assays with High- Speed Separation Method and High Throughput Tray Setup
IgG Purity/Heterogeneity and SDS-MW Assays with High- Speed Separation Method and High Throughput Tray Setup High Throughput Methods to Maximize the Use of the PA 800 Plus system Jose-Luis Gallegos-Perez
More informationTechnical Challenges in the Development of Biosimilars. E. Morrey Atkinson, PhD Interphex May 1, 2012
Technical Challenges in the Development of Biosimilars E. Morrey Atkinson, PhD Interphex May 1, 2012 FDA Guidance on Biosimilarity Guidance for Industry: Scientific Consideration in Demonstrating Biosimilarity
More informationAnalysis of Monoclonal Antibody Charge Variants by Capillary Zone Electrophoresis
Analysis of Monoclonal Antibody Charge Variants by Capillary Zone Electrophoresis Marcia R Santos Global Tactical Marketing, Beckman Coulter Life Sciences, Brea, CA USA INTRODUCTION Charge heterogeneity
More informationAn FDA perspective on the implementation of state-of-the-art analytical methods for therapeutic proteins
Engineering Conferences International ECI Digital Archives Regulatory Sciences for Biologics and Vaccines: Accelerating Development and Enabling Manufacturing Innovation Proceedings 4-25-2017 An FDA perspective
More informationComparison of Different Brands of Carrier Ampholytes for Monoclonal Antibody Charge Heterogeneity Analysis by Capillary Isoelectric Focusing
Comparison of Different Brands of Carrier Ampholytes for Monoclonal Antibody Charge Heterogeneity Analysis by Capillary Isoelectric Focusing Application Note Biotherapeutics & Biosimilars Author Christian
More informationRediscover the Strengths of Your PA 800 Plus - A Multi-Attribute Protein Analyzer
Rediscover the Strengths of Your PA 800 Plus - A Multi-Attribute Protein Analyzer Marcia R Santos SCIEX Separations, Brea, CA Introduction Capillary Electrophoresis is a well-accepted analytical separation
More informationApplication Note. Abstract. Author. Biopharmaceutical
Innovator and Biosimilar Monoclonal Antibody-Peptide Map Comparison Using the Agilent 70 Capillary Electrophoresis System and Agilent MatchCompare Software Application Note Biopharmaceutical Author Arunkumar
More informationRegulatory perspective on setting clinically relevant specifications. Joslyn Brunelle, PhD Team Leader Office of Biotechnology Products
Regulatory perspective on setting clinically relevant specifications Joslyn Brunelle, PhD Team Leader Office of Biotechnology Products Disclaimer The views and opinions expressed should not be used in
More informationComparability of Biotechnology Derived Protein Products: Lessons from the U.S Experience
Comparability of Biotechnology Derived Protein Products: Lessons from the U.S Experience WCBP 2010, 14th Symposium on the Interface of Regulatory and Analytical Sciences for Biotechnology Health Products
More informationWrap Up Summary CMC Strategy Forum. Bridging Analytical Methods Jan 27, 2014
Wrap Up Summary CMC Strategy Forum Bridging Analytical Methods Jan 27, 2014 Common Messages Industry and Regulatory Method lifecycle includes several elements that occur over time as needed to assure accurate,
More informationMonoclonal Antibody Charge Variants Identification by Fully Automated Capillary Isoelectric Focusing Mass Spectrometry
Application Note Pharma & Biopharma Monoclonal Antibody Charge Variants Identification by Fully Automated Capillary Isoelectric Focusing Mass Spectrometry Authors Tony Wang, James Xia, and Rena Wang CMP
More informationTable 1: CE-MS: Unexploited Opportunities in Process Development?
Table 1: CE-MS: Unexploited Opportunities in Process Development? Session 1 Facilitator: Mei Han, Amgen Inc. Scribe: Yunan Wang, Amgen Inc. Session 2 Facilitator: Göran Hübner, Boehringer Ingelheim Pharma
More informationAutomated and quantitative
Automated and quantitative analysis of biologics. PA 800 plus Pharmaceutical Analysis System Genomics Cell Analysis Particle Characterization Capillary Electrophoresis Lab Automation Centrifugation Bioseparation
More informationdeltadot ANTIBODY ANALYSIS Application Note: Antibodies using LABEL FREE INTRINSIC IMAGING LONDON United Kingdom
ANTIBODY ANALYSIS using LABEL FREE INTRINSIC IMAGING Application Note: Antibodies Ana l y s i s o f Im m u n o g l o b u l i n G u s i n g deltadot s PEREGRINE I 512-p i x e l La b e l Fr e e Ca p i l
More informationHigh-resolution Analysis of Charge Heterogeneity in Monoclonal Antibodies Using ph-gradient Cation Exchange Chromatography
High-resolution Analysis of Charge Heterogeneity in Monoclonal Antibodies Using ph-gradient Cation Exchange Chromatography Agilent 1260 Infinity Bio-inert Quaternary LC System with Agilent Bio Columns
More informationRegulatory Updates for Biopharmaceutical Products:FDA Perspective
Regulatory Updates for Biopharmaceutical Products:FDA Perspective CMC Strategy Forum Europe 2016 Sarah Kennett Division of Biotechnology Review and Research I Office of Biotechnology Products OPQ,CDER,
More informationAutomated and Quantitative Analysis of Biologics
PA 800 PLUS PHARMACEUTICAL ANALYSIS SYSTEM Automated and Quantitative Analysis of Biologics PA 800 PLUS PHARMACEUTICAL ANALYSIS SYSTEM For Research Use Only. Not for use in diagnostic procedures. Flexibility
More informationVICH Topic GL40. at Step 7 GUIDELINE ON TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR NEW BIOTECHNOLOGICAL/BIOLOGICAL VETERINARY MEDICINAL PRODUCTS
European Medicines Agency Veterinary Medicines and Inspections London, 15 November 2005 Doc. Ref. EMEA/CVMP/VICH/811/04- corrigendum 1 VICH Topic GL40 at Step 7 GUIDELINE ON TEST PROCEDURES AND ACCEPTANCE
More informationPAVING THE WAY FOR ASSESSING IN VIVO DYNAMICS OF MULTIPLE QUALITY ATTRIBUTES FOR PROTEIN THERAPEUTICS
PAVING THE WAY FOR ASSESSING IN VIVO DYNAMICS OF MULTIPLE QUALITY ATTRIBUTES FOR PROTEIN THERAPEUTICS CASSS Mass Spec September 21, 2017 Haihong Zhou Principal Scientist, Biologics, Vaccines & Bioanalytics
More informationCase Study: A Phase-Driven Approach to the Development and Lifecycle Management of Potency Assays. Spring in New England!!!
Case Study: A Phase-Driven Approach to the Development and Lifecycle Management of Potency Assays CASSS Bioassays 2016: Scientific Approaches & Regulatory Strategies Session Potency Assays: Cell-based
More informationAntibody-drug Conjugates: Characterization and Control Strategies of Lysine-linked Products
Antibody-drug Conjugates: Characterization and Control Strategies of Lysine-linked Products Fred Jacobson Protein Analytical Chemistry Genentech, Inc. CASSS CMC Strategy Forum Japan 2013 December 9-10,
More informationBiochromatography Bring more Zen into your life and laboratory
Seminar Biochromatography Bring more Zen into your life and laboratory Method development and maintaining peptide, protein, glycan and anti-body analyses by LC or LC-MS can be very time consuming and might
More informationReplacing Analytical Methods for Release and Stability Testing CBER Perspective
Replacing Analytical Methods for Release and Stability Testing CBER Perspective Presentation at the CMC Strategy Forum January 27, 2014 Lokesh Bhattacharyya Chief, Lab of Analytical Chemistry and Blood
More informationReference Standards for Monoclonal Antibodies: Key Challenges Addressed
CASSS WCBP 2012: 16th Symposium on the Interface of Regulatory and Analytical Sciences for Biotechnology Health Products January 23-25, 2012 Reference Standards for Monoclonal Antibodies: Key Challenges
More informationQBD BIOLOGICS: REGULATORY PERSPECTIVE. 8Jun2015 Mark Alasandro
QBD BIOLOGICS: REGULATORY PERSPECTIVE 8Jun2015 Mark Alasandro Acknowledgements Thomas Little Dilip Choudhury Curt Monnig Others Outline Regulatory Perspective Building a QbD based Infrastructure Regulatory
More informationUnderstanding the Characteristics and Establishing Acceptance Criteria for Analytical Methods Validation
Understanding the Characteristics and Establishing Acceptance Criteria for Analytical Methods Validation Ying Verdi IVT LAB WEEK EUROPE June 2017 Partners in Health Since 1919 Regulatory View of Method
More informationControl strategy and validation. Emanuela Lacana PhD Office of Biotechnology Products CDER/FDA
Control strategy and validation Emanuela Lacana PhD Office of Biotechnology Products CDER/FDA 1 Disclaimer The views and opinions expressed in this presentation are those of the speaker and should not
More informationPost translational Modifications of Biologics: Impact on clinical safety and efficacy
Post translational Modifications of Biologics: Impact on clinical safety and efficacy Narendra Chirmule, PhD Senior Vice President Head of R&D Biocon, Bangalore, India 1 Extensive post translational modifications
More information"VUPNBUFE BOE RVBOUJUBUJWF
"VUPNBUFEBOERVBOUJUBUJWF BOBMZTJTPGCJPMPHJDT 1" plus1ibsnbdfvujdbm"obmztjt4ztufn Genomics Cell Analysis Particle Characterization Capillary Electrophoresis Lab Automation Centrifugation Bioseparation Lab
More informationANTIBODY DRUG CONJUGATES AND BISPECIFIC ANTIBODIES: SCIENTIFIC & REGULATORY CHALLENGES AND OPPORTUNITIES
ANTIBODY DRUG CONJUGATES AND BISPECIFIC ANTIBODIES: SCIENTIFIC & REGULATORY CHALLENGES AND OPPORTUNITIES Brian DiPaolo 08 June 2017 CASSS Midwest Discussion Group Agenda Introduction Antibody Drug Conjugates
More informationfor the development, characterization, and release of biopharmaceuticals PhD. Emilio Medina-Rivero Principal Scientist Analytical Development R&D
CE for the development, characterization, and release of biopharmaceuticals PhD. Emilio Medina-Rivero Principal Scientist Analytical Development R&D Agenda 1. Capillary Zone Electrophoresis for physicochemical
More informationEGA s Perspective on the Draft Quality Guideline
EGA s Perspective on the Draft Quality Guideline London, 31 October 2013 JOERG WINDISCH, Ph.D. Chief Science Officer, Sandoz Biopharmaceuticals Chair European Biosimilars Group (EBG), EGA Sector Group
More informationKnow-how and Best Practice to Serve our Clients
BioChem Analytical Laboratory Know-how and Best Practice to Serve our Clients BioChem Analytical Laboratory Leading in all Disciplines One laboratory, three disciplines: Everything under one roof - competent,
More informationMonoclonal Antibody Analysis on a Reversed-Phase C4 Polymer Monolith Column
Monoclonal Antibody Analysis on a Reversed-Phase C4 Polymer Monolith Column Shane Bechler 1, Ken Cook 2, and Kelly Flook 1 1 Thermo Fisher Scientific, Sunnyvale, CA, USA; 2 Thermo Fisher Scientific, Runcorn,
More informationTony Mire-Sluis Vice President, Corporate, Product and Device Quality Amgen Inc
The Regulatory Implications of the ever increasing power of Mass Spectrometry and its role in the Analysis of Biotechnology Products Where do we draw the line? Tony Mire-Sluis Vice President, Corporate,
More informationAdvanced QA/QC characterization MS in QC : Multi Attribute Method
Advanced QA/QC characterization MS in QC : Multi Attribute Method Global BioPharma Summit The world leader in serving science A Complex Problem: Drug Safety and Quality Safety Is the product safe to use?
More informationHPCE-5 2. A Revolution in Capillary Electrophoresis. High Performance Capillary Electrophoresis
A Revolution in Capillary Electrophoresis High Performance Capillary Electrophoresis Revolutionary Performance Continuous Monitoring of Capillary and Buffer Conditions Sensitive Label-Free 512 Times Better
More informationDevelop A Highly Similar" Biosimilar Compound: Lessons Learnt
Develop A Highly Similar" Biosimilar Compound: Lessons Learnt Hui-Chun Li, Ph.D. Sr. Manager of Process Science 2015 Feb 05 3rd Biologics World Taiwan 2015 SPIN OFF ACQUISITION Development Center for Biotechnology
More informationThermo Scientific MAbPac HIC Columns. Novel Hydrophobic Interaction HPLC Columns. Designed for Monoclonal Antibody Analysis
Thermo Scientific MAbPac HIC Columns Novel Hydrophobic Interaction HPLC Columns Designed for Monoclonal Antibody Analysis Introduction The Thermo Scientific MAbPac HIC column family is designed for separations
More informationCASE STUDY: THE USE OF PRIOR KNOWLEDGE IN ESTABLISHMENT OF AN INTEGRATED CONTROL STRATEGY AND CLINICALLY RELEVANT SPECIFICATIONS
CASE STUDY: THE USE OF PRIOR KNOWLEDGE IN ESTABLISHMENT OF AN INTEGRATED CONTROL STRATEGY AND CLINICALLY RELEVANT SPECIFICATIONS BARBARA RELLAHAN MS, PHD DIRECTOR, PRODUCT QUALITY PRESENTATION OUTLINE
More informationRegulatory Consideration for the Characterization of HOS in Biotechnology Products
Regulatory Consideration for the Characterization of HOS in Biotechnology Products Maria Teresa Gutierrez Lugo, Ph.D. OBP/CDER/FDA 5 th International Symposium on Higher Order Structure of Protein Therapeutics
More informationOne-stop cief and CE-SDS. One-day method dev. Results in a snap. FDA, PDQ.
One-stop cief and CE-SDS. One-day method dev. Results in a snap. FDA, PDQ. Meet Maurice. He s a real problem solver. Need CE-SDS and cief info on mabs, ADCs and vaccines? Done. He ll even up you one and
More informationCapillary Electrophoresis of Proteins
Capillary Electrophoresis of Proteins SDS Capillary Gel Electrophoresis SDS-CGE Outline CE-SDS Gel Analysis Description of Technique Method Development Tips PA800 plus kits SDS-MW IgG Purity & Heterogeneity
More informationDevelop a Roadmap to Analytical Method Validation Phase Part 1: Method Validation Process
Develop a Roadmap to Analytical Method Validation Phase Part 1: Method Validation Process IVT Conference September 2014 Amir Malek, Ph.D. Analytical Development and Quality Control Outline: Section 1 Page
More informationCOPYRIGHTED MATERIAL QUALITY BY DESIGN: AN OVERVIEW OF THE BASIC CONCEPTS. Rohin Mhatre and Anurag S. Rathore 1.1 INTRODUCTION
1 1.1 INTRODUCTION QUALITY BY DESIGN: AN OVERVIEW OF THE BASIC CONCEPTS Rohin Mhatre and Anurag S. Rathore The premise of Quality by Design (QbD) is that the quality of the pharmaceutical product should
More informationAgilent Technologies. Carl Myerholtz, Ph.D. Senior Director of QTOF Technology. FAPESP/Agilent Workshop August 30,
Agilent Technologies Carl Myerholtz, Ph.D. Senior Director of QTOF Technology FAPESP/Agilent Workshop August 30, 2017 1 FAPESP/Agilent - Call for Research Proposals Focus Areas Biopharma Metabolomics In
More informationGet there, faster with ice3
Get there, faster with ice3 Method development in hours, not weeks. The ice3 Tomorrow s challenges are always looming, so why not catapult ahead? ice3 lets you move beyond the limits of traditional protein
More informationIntelligent Disulfide Bond Analysis
Intelligent Disulfide Bond Analysis Why Study Disulfide Bonds? Save Money by making cell cultures more efficient! Regulations Process Control Higher Quality biotherapeutics Efficacy Protect from Competition
More informationCapillary Electrophoresis in Quality Control PART II: CE-SDS: Method Development and Robustness
Capillary Electrophoresis in Quality Control PART II: CE-SDS: Method Development and Robustness Chantal Felten *1 and Oscar Salas Solano 2 1 Alpine Analytical Acadamy, Whistler, British Columbia 2 Seattle
More informationImpurity Detection with a New Light Emitting Diode Induced Fluorescence Detector Coupled to the Agilent 7100 Capillary Electrophoresis System
Impurity Detection with a New Light Emitting Diode Induced Fluorescence Detector Coupled to the Agilent 7100 Capillary Electrophoresis System Application Note Biologics & Biosimilars, Proteomics & Protein
More informationHOST CELL PROTEIN & BIOPROCESSING REAGENT DEVELOPMENT
HOST CELL PROTEIN & BIOPROCESSING REAGENT DEVELOPMENT INTRODUCTION Biopharmaceuticals require products to be free of residual host cell protein (HCP) contaminants from the bioprocessing workflow. To evaluate
More information